Ajanta Pharma Ltd Share Price – NSE  / BSE

Pharmaceuticals, Small Cap

Net profit of Ajanta Pharma rose 18.09% to Rs 245.77 crore in the quarter ended June 2024 as against Rs 208.12 crore during the previous quarter ended June 2023. Sales rose 12.13% to Rs 1144.92 crore in the quarter ended June 2024 as against Rs 1021.04 crore during the previous quarter ended June 2023.

Powered by Capital Market - Live News

Profit before tax increased 19.73% YoY to Rs 322.12 crore in Q1 FY25.

EBITDA stood at Rs 330 crore in Q1 FY25, up 22% as against 271 crore posted in same quarter last year. EBITDA margin was at 29% in Q1 FY25 as against 27% in Q1 FY24.

During the quarter, the company’s revenue from India stood at Rs 353 crore (up 10% YoY), revenue from Asia was at Rs 277 crore ( up 9% YoY), income from Africa stood at Rs 230 crore (up 45% YoY) while revenue from United States was at Rs 228 crore ( up 7% YoY).

Research and development (R&D) expenses were at Rs 51 crore in Q1 FY25, 4.50% of revenue.

Ajanta Pharma is a specialty pharmaceutical formulation company primarily with a well-diversified branded generics business spread across India, the Rest of Asia, and Africa. The company is involved in development, manufacturing and marketing of marketing of quality finished dosages in domestic and international markets. It produces a comprehensive range of specialty products targeting different therapeutic segments.

The scrip hit an all-time high at Rs 2576.25 in intraday today.

Powered by Capital Market - Live News

Ajanta Pharma will hold a meeting of the Board of Directors of the Company on 30 July 2024.

Powered by Capital Market - Live News

Ajanta Pharma announced that the 45th Annual General Meeting (AGM) of the company will be held on 18 July 2024.

Powered by Capital Market - Live News